Patents Assigned to The Pirbright Institute
  • Patent number: 10507237
    Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: December 17, 2019
    Assignee: The Pirbright Institute
    Inventors: Charles Abrams, Ana-Luisa Reis, Chris Netherton, Linda Dixon, Dave Chapman, Pedro Sanchez-Cordon
  • Patent number: 10294277
    Abstract: The present invention relates to the stabilization of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilized FMDV capsids and vaccines against FMD.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: May 21, 2019
    Assignee: The Pirbright Institute
    Inventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
  • Publication number: 20190135874
    Abstract: The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 9, 2019
    Applicant: Pirbright Institute
    Inventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
  • Patent number: 10202578
    Abstract: The present Invention provides as avian cell in which the expression or activity of one or more of the following genes, or a homologue thereof: Chicken IFITM 1 (SEQ ID No. 1); Chicken IFITM2 (SEQ ID No. 2) and Chicken IFITM3 (SEQ ID No. 3) is reduced. The invention also provides methods for passaging viruses in avian cells, embryos and/or avian cell lines which have reduced expression of one or more IFITM genes and methods which involve investigating the sequence of one or more of the following genes, or a homologue thereof: Chicken IFITM1 (SEQ ID No. 1); Chicken IFITM2 (SEQ ID No. 2) and Chicken IFITM3 (SEQ ID No. 3).
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: February 12, 2019
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Mark Fife, Mark Gibson
  • Patent number: 10130701
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 20, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Patent number: 9969777
    Abstract: The present invention provides an infectious bronchitis virus (IBV) spike protein (S protein) which is based on an S protein from an IBV strain with restricted tissue tropism, but which comprises the sequence XBBXBX in the part of the S2 protein corresponding to residues 686 to 691 of the sequence given as SEQ ID No. 2, where B is a basic residue and X is any amino acid; and which comprises at least one of the following amino acid substitutions with reference to the position numbering of SEQ ID NO:2: Leucine (L) to Phenylalanine (F) at position 578 Asparagine (N) to Serine (S) at position 617 Asparagine (N) to Serine (S) at position 826 Leucine (L) to Phenylalanine (F) at position 857 and Isoleucine (I) to Valine (V) at position 1000 such that an IBV virus comprising the S protein has extended tissue tropism. The present invention also provides a virus comprising such an S protein.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: May 15, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Paul Britton, Erica Bickerton
  • Publication number: 20170136114
    Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.
    Type: Application
    Filed: June 19, 2015
    Publication date: May 18, 2017
    Applicant: THE PIRBRIGHT INSTITUTE
    Inventors: Charles Abrams, Anna-Luisa Reis, Chris Netherton, Linda Dixon, Dave Chapman, Pedro Sanchez-Cordon
  • Patent number: 9457075
    Abstract: The present invention provides a foot-and-mouth diseases virus (FMDV) VP1 capsid protein which comprises an entity of interest (EOI). The EOI sequence may, for example, be an epitope tag, an immunomodulatory molecule or a target molecule. The present invention also provides an FMDV vaccine which comprises such a VP1 capsid protein and its use to prevent FMD.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: October 4, 2016
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Julian Seago, Nicholas Juleff
  • Publication number: 20160052973
    Abstract: The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 25, 2016
    Applicant: Pirbright Institute
    Inventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
  • Patent number: 9243230
    Abstract: The present invention provides a construct which, when expressed in a host cell, is capable of producing empty virus capsids, the construct comprising: (i) a nucleotide sequence encoding a capsid precursor protein; (ii) a nucleotide sequence encoding a protease capable of cleaving the capsid precursor protein; and (iii) a control element which controls the expression of the protease such that, when the construct is present in the host cell, the control element causes the protease to be expressed at a level sufficient to cleave the capsid precursor protein, but not sufficient to induce significant toxicity in the host cell. The invention also provides a vector and a host cell comprising such a construct and their use to generate empty virus capsids.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: January 26, 2016
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Bryan Charleston, Ian Jones
  • Patent number: 9145548
    Abstract: The present invention provides a foot and mouth disease (FMD) virus having improved stability compared to the field isolate of the same subtype, wherein the virus comprises one or more amino acid mutations along a line of symmetry of the capsid structure. The present invention also relates to a vaccine comprising such an FMD virus and its use to prevent foot and mouth disease.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: September 29, 2015
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Veronica Fowler, Nick Knowles, Paul Barnett
  • Patent number: 8828407
    Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: September 9, 2014
    Assignee: The Pirbright Institute
    Inventors: Paul Britton, Erica Bickerton, Maria Armesto
  • Publication number: 20140219918
    Abstract: The present invention provides a foot-and-mouth diseases virus (FMDV) VP1 capsid protein which comprises an entity of interest (EOI). The EOI sequence may, for example, be an epitope tag, an immunomodulatory molecule or a target molecule. The present invention also provides an FMDV vaccine which comprises such a VP1 capsid protein and its use to prevent FMD.
    Type: Application
    Filed: June 26, 2012
    Publication date: August 7, 2014
    Applicant: THE PIRBRIGHT INSTITUTE
    Inventors: Julian Seago, Nicholas Juleff
  • Publication number: 20140189898
    Abstract: The present invention provides a method of identifying an animal having a genotype associated with resistance to bacterial infection comprising the steps of: (a) providing a sample from said animal; (b) determining the alleles at one or more markers of the SAL1 locus to identify the genotype of the marker, wherein said SAL1 locus lies between 54.0 MB to 54.8 MB of chicken Chromosome 5 or an equivalent thereof; and (c) determining whether the genotype is a genotype associated with resistance to bacterial infection.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 3, 2014
    Applicant: The Pirbright Institute
    Inventors: Mark Fife, Peter Kaiser, Nigel Salmon
  • Publication number: 20130230549
    Abstract: The present invention provides a foot and mouth disease (FMD) virus having improved stability compared to the field isolate of the same subtype, wherein the virus comprises one or more amino acid mutations along a line of symmetry of the capsid structure. The present invention also relates to a vaccine comprising such an FMD virus and its use to prevent foot and mouth disease.
    Type: Application
    Filed: September 8, 2011
    Publication date: September 5, 2013
    Applicant: THE PIRBRIGHT INSTITUTE
    Inventors: Veronica Fowler, Nick Knowles, Paul Barnett
  • Publication number: 20130216569
    Abstract: The present invention provides a polypeptide comprising the amino acid sequence as shown as SEQ ID No. 1 or a homologue or fragment thereof, a nucleic acid capable of encoding such a polypeptide and a vaccine comprising such a polypeptide/nucleic acid. The vaccine may be used for the treatment and/or prevention of a disease associated with an apicomplexan parasite.
    Type: Application
    Filed: August 2, 2011
    Publication date: August 22, 2013
    Applicant: THE PIRBRIGHT INSTITUTE
    Inventors: Damer Blake, Adrian Smith, Martin Shirley
  • Patent number: 8501466
    Abstract: The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: August 6, 2013
    Assignee: The Pirbright Institute
    Inventors: Venugopal Nair, Luke Lambeth
  • Patent number: 8455201
    Abstract: The present invention provides a method for diagnosing a mycobacterial infection in a subject, involving the following steps: (i) collection of a sample from the subject; (ii) incubation of the sample from (i) with an antigen preparation for 12 hours or less; and (iii) analysis of ?-IFN in the sample from (ii). The invention also provides a diagnostic kit for use in such a method.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: June 4, 2013
    Assignee: The Pirbright Institute
    Inventors: Jayne Hope, Paul Sopp, Chris Howard